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Anaemia and absolute or functional iron deficiency (ID) are common issues among cancer patients, 
with the prevalence of ID ranging from 32% to 60%. Most randomised clinical trials have shown 
superior efficacy of IV iron over oral or no iron supplementation in anaemic cancer patients receiving 
erythropoiesis-stimulating agents. Intravenous iron supplementation reduced blood transfusions, 
increased haemoglobin, and improved quality of life. At recommended doses, IV iron is well 
tolerated, and allergic reactions are exceedingly rare with modern formulations. Oral iron is often 
poorly tolerated and this can lead to compliance issues. 
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Cancer patients, especially those
receiving chemotherapy, frequently suffer 
from anaemia and iron deficiency (ID).1,2 
Reports on the prevalence of ID are still 
scarce but estimates range from 29% to 
60%, depending on the tumour type and 
patient population.1 Nevertheless, the role 
of ID seems to be underestimated, 
although data in cancer patients suggest a 
significant correlation between ID and 
worse World Health Organization (WHO) 
performance scores.3 Even in non-anaemic 
healthy individuals, ID can be associated 
with impaired physical function and 
fatigue that respond to iron therapy.1 The 
importance of iron in anaemia 
management is increasingly recognised 
and anaemia treatment guidelines 
recommend minimising the use of 
erythropoiesis-stimulating agents (ESAs) 
and blood transfusions because of the 
associated risks.4–6
Pathophysiology and diagnosis
Chronic blood loss and nutritional 
deficiencies can aggravate anaemia in 
cancer patients; however, anaemia of 
chronic disease (ACD) and chemotherapy-
induced anaemia (CIA) are the major 
causes. Chronic diseases, including cancer, 
are associated with proinflammatory 
cytokine patterns, which, in turn, 
upregulate hepcidin, the key regulator of 
iron homeostasis. As a consequence of 
high hepcidin levels, iron cannot be 
mobilised sufficiently from physiological 
iron stores in cancer patients,7 especially in 
patients treated with an ESA who have an 
elevated demand for iron due to rapidly 
increased red blood cell production. 
Because hepcidin also affects the release of 
iron from enterocytes, the absorption of 
nutritional iron and oral iron preparations 
is also impaired, thereby further increasing 
the risk of ID and anaemia. Routine 
diagnosis of ID has to identify both 
insufficient iron stores for successful ESA 
therapy and insufficient availability of iron 
for effective erythropoiesis. Depleted iron 
stores are indicated by serum ferritin 
levels <100ng/ml (absolute iron 
deficiency), whereas insufficient 
availability of iron is indicated by low 
transferrin saturation (TSAT <20%) even 
if serum ferritin levels are normal or 
elevated (often referred to as functional 
iron deficiency; FID).1 Other markers of 
iron-restricted erythropoiesis are not 
recommended in daily practice.
Treatment of ID and anaemia
Treatment options for anaemia in cancer 
patients include blood transfusions, ESAs 
and iron supplementation. However, a 
main goal of anaemia treatment guidelines 
is reducing the reliance on blood 
transfusions.4–6 Transfusions still bear 
risks such as transfusion reactions and 
transmission of known and unknown 
infectious diseases, and may increase the 
risk of cancer recurrence, mortality, stroke 
and myocardial infarction.1,8
One option to reduce transfusion 
requirements of cancer patients is the 
addition of ESAs to therapy, yet the 
European Medicines Agency (EMA) 
highlighted that ESA use should be 
restricted for cancer patients with clearly 
symptomatic anaemia who receive 
chemotherapy.1 Furthermore, initiation of 
ESAs is limited to patients with 
haemoglobin (Hb) <10g/dl and dose 
reductions are required if Hb increase is 
≥1g/dl within two weeks. Limits in 
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response rate (30–75%, probably due to 
absolute or functional ID), can be 
overcome with IV iron, as acknowledged 
by anaemia treatment guidelines in 
oncology.4–6 Intravenous iron should be 
particularly considered in patients with 
FID (that is, ferritin levels up to 800ng/ml 
if TSAT is <20%). Active infection is 
considered as the only restriction to iron 
supplementation.1 
The efficacy of IV iron supplementation 
in cancer patients treated with ESAs for 
chemotherapy- or cancer-related anaemia 
has been shown in six randomised, 
controlled clinical trials.1 Notably, studies 
in patients who were not iron-deficient at 
enrolment achieved a 13–19% absolute 
increase in response rate, confirming that 
high IV iron doses can overcome hepcidin-
mediated reduction of iron release from 
the reticuloendothelial system. Only one 
study using an unusual (off-label) dosing 
schedule did not show a significant benefit 
of IV iron supplementation.9
An oral iron arm was included in three 
of these studies9–11 and did not show a 
significant benefit of oral iron compared 
with no iron supplementation. Conversely, 
IV iron, given at recommended doses, 
significantly improved haematologic 
response compared with oral and no iron 
supplementation.10,11 Therefore, oral iron 
might only be considered in patients with 
absolute ID and adequate tolerance of oral 
iron but no impairment of iron resorption 
and no, or only minor, symptoms. 
ESA-treated patients (receiving 
concomitant chemotherapy) who have ID 
should receive IV iron therapy.5 Meta-
analyses of publications and abstracts on 
trials comparing IV iron with no or oral 
iron supplementation of ESA therapy 
(including the seven studies discussed 
above) showed a significantly increased 
chance (29–31%) to achieve a 
haematopoietic response with IV iron 
supplementation, and a 23% reduction in 
the risk of transfusion.1
Dosing of IV iron
Most studies on IV iron supplementation 
used a total dose of approximately 1000mg 
iron.1 One study compared multiple 
administrations of 100mg iron with a total 
dose infusion of 1000–3000mg and found 
no difference in haematologic response.12 
Therefore, we recommend a single dose of 
1000mg iron (if feasible with the available 
IV iron formulations; Table 1) in patients 
with functional iron deficiency. If no 
haemoglobin response is observed six 
weeks after initial treatment, iron status 
parameters should be checked. In patients 
with absolute iron deficiency, we 
recommend following the product label.
Sole or supplemental treatment with 
IV iron?
In anaemic cancer patients with ID, 
guidelines recommend treatment of ID 
before initiation of an ESA. Because 
impaired iron utilisation is a main cause of 
anaemia, iron treatment alone may already 
serve as anaemia treatment. In non-cancer 
populations with chronic disease 
(inflammatory bowel disease, chronic 
heart failure), IV iron as sole anaemia 
treatment could resolve anaemia. In 
cancer patients, however, studies 
examining IV iron as sole anaemia 
treatment are only just starting to emerge. 
Two small studies in patients with 
gynaecologic cancers showed promising 
results, and a recent report suggests that 
IV iron supplementation without addition 
of an ESA might improve Hb levels in 
patients with cancer.13
Economic aspects of IV iron  
in anaemia therapy
Anaemia significantly increases annual 
healthcare costs ($34,009 versus $9,034 
for anaemic versus non-anaemic cancer 
patients; p<0.001)14 and ESAs are a major 
cost factor. Treatment supplementation 
with IV iron can reduce ESA dose (and 
transfusion) requirements and thereby 
result in substantial cost savings in the 
treatment of cancer-related anaemia.1,15 
Among the different IV iron 
preparations, the number and duration 
of required infusions mainly influence 
the treatment costs.16
Safety of IV iron in clinical routine
The tolerability of IV iron in ESA-treated 
patients has been confirmed in six 
randomised, controlled clinical trials. No 
differences in adverse event rates were 
observed between IV iron and control 
treatment arms.1 One trial that reported 
higher adverse event rates in the IV iron 
arm used high individual doses of sodium 
ferric gluconate that exceeded the 
recommended dose by 50% (187.5 
compared with 125 mg iron per 
administration).1,9 Intravenous iron 
infusions can be associated with adverse 
infusion reactions. In routine practice, 
allergic and anaphylactoid reactions are 
rare and mainly associated with iron 
dextrans. A recent study that analysed 
adverse events reports separately for 
Europe and North America showed a 
higher rate of anaphylactic reactions also 
for low molecular weight iron dextrans 
(15.6 events per million 100mg iron dose 
equivalents) compared with iron sucrose 
and ferric gluconate (0.9 and 0.4 events 
per million 100mg iron dose equivalents, 
respectively).17
Oral iron is well known for its 
gastrointestinal intolerance, which also 
affects patients’ adherence with therapy.1 
Among studies investigating oral and IV 
iron in ESA-treated anaemic cancer 
patients, Henry et al11 reported drug-
related adverse events in 31.1% of patients 
Table 1: Approved IV iron preparations





Sodium ferric gluconate Ferlecit 
Ferumoxytol* Rienso*
INN, International Non-proprietary Name of active substance
* Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the 
granting of a marketing authorisation
Intended copies of originator IV iron compounds have been approved via the generic pathway in different 
countries. Because subtle differences in the manufacturing process can affect the physicochemical and 
biological properties of these compounds, clinical head-to-head comparisons between the copies and the 
reference product are recommended for confirmation of therapeutic and toxicologic equivalence.1
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in the oral iron arm compared with 12.7% 
in the IV iron arm (no details on statistical 
significance of the difference were 
reported).
Limitations to the use of IV iron  
in clinical practice
Although not specifically investigated in 
human studies, potential interactions of 
iron with cells of the immune system and 
certain chemotherapies (for example, 
anthracyclines and platinum-based 
therapies) may be considered as limits to 
IV iron use until availability of human 
data.1,7 In clinical trials, no increased rate 
of infections was observed in IV iron-
treated cancer patients but animal studies 
suggest that IV iron administration should 
be avoided during active sepsis. In patients 
receiving cardiotoxic chemotherapy, 
concomitant administration of IV iron and 
cytotoxic drug therapy may be avoided, 
and IV iron given either before 
administration of chemotherapy or at the 
end of a treatment cycle; just before the 
next cycle.1
Some epidemiological studies showed 
that conditions with long-term iron 
overload are associated with the 
induction of new cancers. This gave rise 
to uncertainty on the potential role of iron 
in tumour progression. A recent clinical 
review has not identified any related 
clinical concern but long-term follow-up 
data in cancer patients are not yet 
available.1
Conclusions
Intravenous iron improved response rates 
to anaemia treatment in published 
randomised, controlled trials, whereas no 
significant benefit of oral iron has been 
seen in the investigated ESA-treated 
cancer patient populations. Furthermore, 
IV iron may be effective in the reduction 
of ESA doses and blood transfusions. 
Results of a few studies that investigated 
the use of IV iron as first-line anaemia 
therapy suggest that IV iron as sole 
anaemia therapy can benefit some 
patients, and addition of an ESA may be 
considered for patients not responding to 
IV iron alone. Nevertheless, confirmation 
of long-term safety requires larger 
randomised, controlled studies with 
long-term follow-up. l
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Key points
•	 	Iron	deficiency	(ID),	especially	functional	iron	deficiency,	is	a	frequent	comorbidity	across	
different tumour types. ID is a main cause of anaemia and associated with worse 
performance status.
•	 	Iron	status	should	be	assessed	at	initial	diagnosis,	and	during	any	kind	of	anti-anaemia	
therapy to warrant timely commencement of iron supplementation.
•	 	In	cancer	patients,	transferrin	saturation	<20%	indicates	insufficient	availability	of	iron	
despite normal or elevated serum ferritin levels (functional iron deficiency). Serum ferritin 
<100ng/ml	probably	indicates	depleted	iron	stores	(absolute	iron	deficiency).
•	 	IV	iron	supplementation	of	ESA	therapy	significantly	increased	haematopoietic	response	
and reduced the risk of blood transfusion. Growing evidence suggests that IV iron 
supplementation without addition of an ESA might improve haemoglobin levels in patients 
with cancer.
•	 	In	cancer	patients,	a	single	dose	of	1000mg	iron	(	if	possible	)	is	recommended	for	the	
treatment of functional iron deficiency. At recommended doses, IV iron is well tolerated; no 
increase in infections or new adverse events were observed in clinical trials.
